405
Participants
Start Date
November 10, 2024
Primary Completion Date
February 24, 2025
Study Completion Date
March 10, 2025
Probiotic Clostridium butyricum CBM588®
This group received probiotic Clostridium butyricum CBM588® treatment for IBS-D as three tablets daily for 8 weeks.
Standard of care IBS-D treatment
Patients in this group received standard of care IBS-D treatment of Trimebutine maleate maleate and followed a lactose-free, no-slag diet.
Quisisana Clinic, Itala
"University of Urbino Carlo Bo"
OTHER
Liaquat University of Medical & Health Sciences
OTHER